Endpoints News2h
J&J’s third talc bank­rupt­cy bid is stopped by Texas fed­er­al judge
A federal judge on Monday dismissed a Johnson & Johnson subsidiary’s third attempt to settle tens of thousands of talc cases ...
Endpoints News4h
Fed­er­al judge nix­es FDA's lab-de­vel­oped test rule, says it ex­ceed­ed agen­cy's au­thor­i­ty
The FDA overstepped its authority when it issued a rule last May to bring laboratory-developed tests under the agency’s ...
Endpoints News6h
DC court sides with HHS in Ver­tex's fer­til­i­ty pro­gram fight
Vertex lost a legal battle against the federal government on Monday over its proposed fertility support program that would ...
Endpoints News7h
Vax­cyte's Phase 2 pneu­mo­coc­cal vac­cine da­ta dis­ap­point Wall Street
Vaxcyte’s stock price dropped by 50% on Monday after the company reported new Phase 2 data from a study evaluating an ...
Endpoints News10h
As­traZeneca’s cho­les­terol pill is set for Phase 3, but lags be­hind Mer­ck ri­val
As­traZeneca has great am­bi­tions for its mid-stage oral cho­les­terol drug, be­liev­ing that it could reach peak sales of ...
Endpoints News10h
Marks’ ex­it at FDA rat­tles an al­ready tee­ter­ing biotech in­dus­try
FDA biologics chief Peter Marks resigns over vaccine dispute with HHS Secretary RFK Jr., causing biotech stocks to drop.
Endpoints News12h
Ver­tex’s sec­ond-gen­er­a­tion di­a­betes cell ther­a­py fails ear­ly-stage study
Vertex halts VX-264 diabetes cell therapy due to poor efficacy in Phase 1/2 study, but continues Phase 3 trial of zimislecel ...
Endpoints News9h
Cor­cept shares soar af­ter Phase 3 win in plat­inum-re­sis­tant ovar­i­an can­cer
Corcept Therapeutics’ oral glucocorticoid receptor antagonist has improved survival outcomes in a late-stage test in patients ...
Endpoints News10h
Lil­ly's heart dis­ease drug could be dosed as lit­tle as once a year, study shows
Phase 2 results on Eli Lilly’s experimental heart disease drug showed it could be dosed far less frequently than competing ...
Endpoints News11h
In­spir­na, which was prepar­ing for a Phase 3 can­cer tri­al, has fold­ed
A New York City drug developer led by well-known executives and backed by some of the top names in biotech investing is ...
Endpoints News11h
LifeM­ine’s re­struc­tur­ing; Eu­rope won’t re­new au­tho­riza­tion for PTC’s Duchenne drug
LifeMine restructures with layoffs; PTC's Translarna is pulled in Europe; Opthea ends AMD trials; Apollomics and LaunXP make ...
Endpoints News22h
Ex­clu­sive: SV Health de­buts Parkin­son's biotech with back­ing from Ab­b­Vie and oth­ers
SV Health Investors, fresh off a $250 million fund for dementia-focused biotechs, has unveiled its latest effort, this time ...